Abstract
The continued HIV/AIDS epidemic worldwide and the battle against emerging infectious diseases caused by coronaviruses underscore the need for the development of an ever-expanding repertoire of antiviral drugs. Entry inhibitors are of particular interest because of their potential to be used as therapeutic or prophylactic treatments for blocking viral invasion. HIV and coronaviruses utilize class I fusion proteins to facilitate their entry and membrane fusion. Discovery of a common hexameric coiled-coil fusion complex resulting from the packing of three C-terminal heptad repeat region from the fusion-mediating subunit of viral fusion proteins against trimeric coiled-coil made up by their N-terminal heptad repeat prompted the search for peptides mimicking the heptad repeat regions that could potentially inhibit viral entry. This has led to the development of effective peptides that are specific to the virus that is developed for. In this review, we focus on peptide-based entry dual inhibitors that block fusion process not only of HIV but also coronaviruses through interrupting their fusogenic six-helical bundle core and which hopefully will help to gain insight into the α-helical secondary structure- and coiled-coil superstructure-based strategies to design entry inhibitors with broad-spectrum antiviral activity against enveloped viruses with class I fusion proteins.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Apostolovic B, Danial M, Klok HA (2010) Coiled coils: attractive protein folding motifs for the fabrication of self-assembled, responsive and bioactive materials. Chem Soc Rev 39(9):3541–3575. https://doi.org/10.1039/b914339b
Bianchi E, Finotto M, Ingallinella P, Hrin R, Carella AV, Hou XS, Schleif WA, Miller MD, Geleziunas R, Pessi A (2005) Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc Natl Acad Sci U S A 102(36):12903–12908. https://doi.org/10.1073/pnas.0502449102
Bosch BJ, Martina BEE, van der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJR, de Groot R, Osterhaus A, Rottier PJM (2004) Severe acute respiratory syndrome coroavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci U S A 101(22):8455–8460. https://doi.org/10.1073/pnas.0400576101
Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89(2):263–273. https://doi.org/10.1016/s0092-8674(00)80205-6
Chen X, Lu L, Qi Z, Lu H, Wang J, Yu X, Chen Y, Jiang S (2010) Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides. J Biol Chem 285(33):25506–25515. https://doi.org/10.1074/jbc.M110.101170
Chong H, Wu X, Su Y, He Y (2016) Development of potent and long-acting HIV-1 fusion inhibitors. AIDS 30(8):1187–1196. https://doi.org/10.1097/QAD.0000000000001073
Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM (2008) Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors. J Cell Biochem 104(6):2335–2347. https://doi.org/10.1002/jcb.21790
De Feo CJ, Weiss CD (2012) Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors. Viruses 4(12):3859–3911. https://doi.org/10.3390/v4123859
Deng Y, Liu J, Zheng Q, Yong W, Lu M (2006) Structures and polymorphic interactions of two heptad-repeat regions of the SARS virus S2 protein. Structure 14(5):889–899. https://doi.org/10.1016/j.str.2006.03.007
Dimitrov DS (2004) Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol 2(2):109–122. https://doi.org/10.1038/nrmicro817
Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguiere AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Muller S, Rickerts V, Sturmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348(20):1967–1976. https://doi.org/10.1056/NEJMoa030747
Dwyer JJ, Wilson KL, Martin K, Seedorff JE, Hasan A, Medinas RJ, Davison DK, Feese MD, Richter HT, Kim H, Matthews TJ, Delmedico MK (2008) Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency. Protein Sci 17(4):633–643. https://doi.org/10.1110/ps.073307608
Eckert DM, Kim PS (2001) Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci U S A 98(20):11187–11192. https://doi.org/10.1073/pnas.201392898
Gao J, Lu G, Qi J, Li Y, Wu Y, Deng Y, Geng H, Li H, Wang Q, Xiao H, Tan W, Yan J, Gao GF (2013) Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J Virol 87(24):13134–13140. https://doi.org/10.1128/JVI.02433-13
Gray GE, Bekker L-G, Laher F, Malahleha M, Allen M, Moodie Z, Grunenberg N, Huang Y, Grove D, Prigmore B, Kee JJ, Benkeser D, Hural J, Innes C, Lazarus E, Meintjes G, Naicker N, Kalonji D, Nchabeleng M, Sebe M, Singh N, Kotze P, Kassim S, Dubula T, Naicker V, Brumskine W, Ncayiya CN, Ward AM, Garrett N, Kistnasami G, Gaffoor Z, Selepe P, Makhoba PB, Mathebula MP, Mda P, Adonis T, Mapetla KS, Modibedi B, Philip T, Kobane G, Bentley C, Ramirez S, Takuva S, Jones M, Sikhosana M, Atujuna M, Andrasik M, Hejazi NS, Puren A, Wiesner L, Phogat S, Diaz Granados C, Koutsoukos M, Van Der Meeren O, Barnett SW, Kanesa-Thasan N, Kublin JG, McElrath MJ, Gilbert PB, Janes H, Corey L (2021) Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120–MF59 in adults. N Engl J Med 384(12):1089–1100. https://doi.org/10.1056/NEJMoa2031499
Harrison SC (2008) Viral membrane fusion. Nat Struct Mol Biol 15(7):690–698. https://doi.org/10.1038/nsmb.1456
Huang X, Dong W, Milewska A, Golda A, Qi Y, Zhu QK, Marasco WA, Baric RS, Sims AC, Pyrc K, Li W, Sui J (2015) Human coronavirus HKU1 spike protein uses o-acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme. J Virol 89(14):7202–7213. https://doi.org/10.1128/JVI.00854-15
Ingallinella P, Bianchi E, Finotto M, Cantoni G, Eckert DM, Supekar VM, Bruckmann C, Carfi A, Pessi A (2004) Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus. Proc Natl Acad Sci U S A 101(23):8709–8714. https://doi.org/10.1073/pnas.0402753101
Jiang S, Lin K, Strick N, Neurath AR (1993) HIV-1 inhibition by a peptide. Nature 365(6442):113. https://doi.org/10.1038/365113a0
Koay WLA, Kose-Otieno J, Rakhmanina N (2021) HIV drug resistance in children and adolescents: always a challenge? Curr Epidemiol Rep:1–11. https://doi.org/10.1007/s40471-021-00268-3
Lai W, Wang C, Yu F, Lu L, Wang Q, Jiang X, Xu X, Zhang T, Wu S, Zheng X, Zhang Z, Dong F, Jiang S, Liu K (2016) An effective strategy for recapitulating N-terminal heptad repeat trimers in enveloped virus surface glycoproteins for therapeutic applications. Chem Sci 7(3):2145–2150. https://doi.org/10.1039/c5sc04046a
Lalezari JP, Henry K, O’Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M, Group TS (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348(22):2175–2185. https://doi.org/10.1056/NEJMoa035026
Lan Q, Pu J, Cai Y, Zhou J, Wang L, Jiao F, Xu W, Wang Q, Xia S, Lu L, Jiang S (2021) Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection. Microbes Infect 23:104840. https://doi.org/10.1016/j.micinf.2021.104840
Li WH, Moore MJ, Vasilieva N, Sui JH, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426(6965):450–454. https://doi.org/10.1038/nature02145
Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P, Jiang S (2004) Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363(9413):938–947. https://doi.org/10.1016/s0140-6736(04)15788-7
Liu S, Lu H, Niu J, Xu Y, Wu S, Jiang S (2005) Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 280(12):11259–11273. https://doi.org/10.1074/jbc.M411141200
Liu S, Jing W, Cheung B, Lu H, Sun J, Yan X, Niu J, Farmar J, Wu S, Jiang S (2007) HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J Biol Chem 282(13):9612–9620. https://doi.org/10.1074/jbc.M609148200
Lu L, Liu Q, Zhu Y, Chan KH, Qin L, Li Y, Wang Q, Chan JF, Du L, Yu F, Ma C, Ye S, Yuen KY, Zhang R, Jiang S (2014) Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 5:3067. https://doi.org/10.1038/ncomms4067
Ma Y, Frutos-Beltran E, Kang D, Pannecouque C, De Clercq E, Menendez-Arias L, Liu X, Zhan P (2021) Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chem Soc Rev 50(7):4514–4540. https://doi.org/10.1039/d0cs01084g
Pessi A (2015) Cholesterol-conjugated peptide antivirals: a path to a rapid response to emerging viral diseases. J Pept Sci 21(5):379–386. https://doi.org/10.1002/psc.2706
Pillaiyar T, Meenakshisundaram S, Manickam M (2020) Recent discovery and development of inhibitors targeting coronaviruses. Drug Discov Today 25(4):668–688. https://doi.org/10.1016/j.drudis.2020.01.015
Pitman MC, Lau JSY, McMahon JH, Lewin SR (2018) Barriers and strategies to achieve a cure for HIV. Lancet HIV 5(6):e317–e328. https://doi.org/10.1016/s2352-3018(18)30039-0
Qi Z, Shi W, Xue N, Pan C, Jing W, Liu K, Jiang S (2008) Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors. J Biol Chem 283(44):30376–30384. https://doi.org/10.1074/jbc.M804672200
Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, Thiel V, Drosten C, Rottier PJ, Osterhaus AD, Bosch BJ, Haagmans BL (2013) Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495(7440):251–254. https://doi.org/10.1038/nature12005
Sanders RW, Moore JP (2021) Virus vaccines: proteins prefer prolines. Cell Host Microbe 29(3):327–333. https://doi.org/10.1016/j.chom.2021.02.002
Serafin MB, Bottega A, Foletto VS, da Rosa TF, Horner A, Horner R (2020) Drug repositioning is an alternative for the treatment of coronavirus COVID-19. Int J Antimicrob Agents 55(6):105969. https://doi.org/10.1016/j.ijantimicag.2020.105969
Shi W, Qi Z, Pan C, Xue N, Debnath AK, Qie J, Jiang S, Liu K (2008) Novel anti-HIV peptides containing multiple copies of artificially designed heptad repeat motifs. Biochem Biophys Res Commun 374(4):767–772. https://doi.org/10.1016/j.bbrc.2008.07.134
Shi W, Cai L, Lu L, Wang C, Wang K, Xu L, Zhang S, Han H, Jiang X, Zheng B, Jiang S, Liu K (2012) Design of highly potent HIV fusion inhibitors based on artificial peptide sequences. Chem Commun (Camb) 48(94):11579–11581. https://doi.org/10.1039/c2cc35973a
Skowronski DM, Astell C, Brunham RC, Low DE, Petric M, Roper RL, Talbot PJ, Tam T, Babiuk L (2005) Severe acute respiratory syndrome (SARS): a year in review. Annu Rev Med 56:357–381. https://doi.org/10.1146/annurev.med.56.091103.134135
Tan K, Liu J, Wang J, Shen S, Lu M (1997) Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A 94(23):12303–12308. https://doi.org/10.1073/pnas.94.23.12303
Tong P, Lu Z, Chen X, Wang Q, Yu F, Zou P, Yu X, Li Y, Lu L, Chen YH, Jiang S (2013) An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides. J Antimicrob Chemother 68(11):2533–2544. https://doi.org/10.1093/jac/dkt230
Wang C, Lai W, Yu F, Zhang T, Lu L, Jiang X, Zhang Z, Xu X, Bai Y, Jiang S, Liu K (2015) De novo design of isopeptide bond-tethered triple-stranded coiled coils with exceptional resistance to unfolding and proteolysis: implication for developing antiviral therapeutics. Chem Sci 6(11):6505–6509. https://doi.org/10.1039/c5sc02220g
Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K (2018) De novo design of alpha-helical lipopeptides targeting viral fusion proteins: a promising strategy for relatively broad-spectrum antiviral drug discovery. J Med Chem 61(19):8734–8745. https://doi.org/10.1021/acs.jmedchem.8b00890
Wang X, Xia S, Wang Q, Xu W, Li W, Lu L, Jiang S (2020) Broad-spectrum coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus diseases. Int J Mol Sci 21(11):3843. https://doi.org/10.3390/ijms21113843
Wang C, Xia S, Wang X, Li Y, Wang H, Xiang R, Jiang Q, Lan Q, Liang R, Li Q, Huo S, Lu L, Wang Q, Yu F, Liu K, Jiang S (2021a) Supercoiling structure-based design of a trimeric coiled-coil peptide with high potency against HIV-1 and human beta-coronavirus infection. J Med Chem. https://doi.org/10.1021/acs.jmedchem.1c00258
Wang X, Xia S, Zhu Y, Lu L, Jiang S (2021b) Pan-coronavirus fusion inhibitors as the hope for today and tomorrow. Protein. Cell 12(2):84–88. https://doi.org/10.1007/s13238-020-00806-7
Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387(6631):426–430. https://doi.org/10.1038/387426a0
Wild C, Oas T, McDanal C, Bolognesi D, Matthews T (1992) A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A 89(21):10537–10541. https://doi.org/10.1073/pnas.89.21.10537
Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ (1994) Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 91(21):9770–9774. https://doi.org/10.1073/pnas.91.21.9770
Xia S, Xu W, Wang Q, Wang C, Hua C, Li W, Lu L, Jiang S (2018) Peptide-based membrane fusion inhibitors targeting HCoV-229E spike protein HR1 and HR2 domains. Int J Mol Sci 19(2):487. https://doi.org/10.3390/ijms19020487
Xia S, Lan Q, Pu J, Wang C, Liu Z, Xu W, Wang Q, Liu H, Jiang S, Lu L (2019a) Potent MERS-CoV fusion inhibitory peptides identified from HR2 domain in spike protein of bat coronavirus HKU4. Viruses 11(1):56. https://doi.org/10.3390/v11010056
Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA, Jiang S, Yang B, Lu L (2019b) A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv 5(4):eaav4580. https://doi.org/10.1126/sciadv.aav4580
Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L (2020a) Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res 30(4):343–355. https://doi.org/10.1038/s41422-020-0305-x
Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S, Lu L (2020b) Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol 17(7):765–767. https://doi.org/10.1038/s41423-020-0374-2
Xu W, Pu J, Su S, Hua C, Su X, Wang Q, Jiang S, Lu L (2019) Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41. AIDS 33(10):1545–1555. https://doi.org/10.1097/QAD.0000000000002208
Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, Rabenau H, Doerr HW, Hunsmann G, Otaka A, Tamamura H, Fujii N, Yamamoto N (2004) HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun 318(3):719–725. https://doi.org/10.1016/j.bbrc.2004.04.083
Yan L, Meng B, Xiang J, Wilson IA, Yang B (2018) Crystal structure of the post-fusion core of the Human coronavirus 229E spike protein at 1.86 A resolution. Acta Crystallogr D Struct Biol 74(Pt 9):841–851. https://doi.org/10.1107/S2059798318008318
Yeager CL, Ashmun RA, Williams RK, Cardellichio CB, Shapiro LH, Look AT, Holmes KV (1992) Human aminopeptidase N is a receptor for human coronavirus 229E. Nature 357(6377):420–422. https://doi.org/10.1038/357420a0
Yu D, Zhu Y, Yan H, Wu T, Chong H, He Y (2021) Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus. Emerg. Microbes Infect 10(1):810–821. https://doi.org/10.1080/22221751.2021.1917309
Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H (2004) Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. Biochem Biophys Res Commun 319(3):746–752. https://doi.org/10.1016/j.bbrc.2004.05.046
Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367(19):1814–1820. https://doi.org/10.1056/NEJMoa1211721
Zhang X, Ding X, Zhu Y, Chong H, Cui S, He J, Wang X, He Y (2019) Structural and functional characterization of HIV-1 cell fusion inhibitor T20. AIDS 33(1):1–11. https://doi.org/10.1097/QAD.0000000000001979
Zheng Q, Deng Y, Liu J, van der Hoek L, Berkhout B, Lu M (2006) Core structure of S2 from the human coronavirus NL63 spike glycoprotein. Biochemistry 45(51):15205–15215. https://doi.org/10.1021/bi061686w
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus I, Research T (2020a) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382(8):727–733. https://doi.org/10.1056/NEJMoa2001017
Zhu Y, Yu D, Yan H, Chong H, He Y (2020b) Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity. J Virol 94(14):e00635–e00620. https://doi.org/10.1128/JVI.00635-20
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Wang, H., Wang, C. (2022). Peptide-Based Dual HIV and Coronavirus Entry Inhibitors. In: Jiang, S., Lu, L. (eds) Virus Entry Inhibitors. Advances in Experimental Medicine and Biology, vol 1366. Springer, Singapore. https://doi.org/10.1007/978-981-16-8702-0_6
Download citation
DOI: https://doi.org/10.1007/978-981-16-8702-0_6
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-8701-3
Online ISBN: 978-981-16-8702-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)